What is Seres Therapeutics's market cap?

Seres Therapeutics (MCRB) has a market capitalization of $47.0M and trades on NASDAQ.

Who are Seres Therapeutics's competitors?

Seres Therapeutics's key competitors include AbbVie, Shattuck Labs, Inc. Common Stock, Spero Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Seres Therapeutics partner with?

Seres Therapeutics's notable partners include Nestlé Health Science, Memorial Sloan Kettering Cancer Center, Crohn’s and Colitis Foundation, and others.

Where is Seres Therapeutics headquartered?

Seres Therapeutics is headquartered in United States of America and employs approximately 233 people. It has been publicly traded since 2015.

Seres Therapeutics

MCRB

Seres Therapeutics is a clinical-stage biotechnology company pioneering the development of live biotherapeutic products (LBPs) designed to treat diseases by modulating the human microbiome.

Market cap

$46.97M-62.6%

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$358.0KIn line EPS-$2.08Miss by $0.20

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$179.0K

EPS estimate-$2.19

Competitors

By market cap

AbbVie$453.91B+36.3%

Shattuck Labs, Inc.$672.4M+1,610%

Cerus$615.1M+137%

Spero Therapeutics, Inc.$68.3M-46.9%

Edesa Biotech, Inc.$51.5M+215%

Seres Therapeutics$47.0M-59.4%

Soligenix, Inc.$5.4M+28.4%

Azitra$2.1M-51.6%

By revenue growth

AbbVie+9.5%

Cerus+1.8%

Shattuck Labs, Inc.-78.3%

By net margin

AbbVie5.79%-1.5pp

Cerus-9.75%+4.9pp

Shattuck Labs, Inc.-4,987.4%-3,454pp

Profile

Seres Therapeutics is a clinical-stage biotechnology company pioneering the development of live biotherapeutic products (LBPs) designed to treat diseases by modulating the human microbiome. The company leverages its proprietary MbTx reverse translational platform to design oral consortia of bacteria that restore the gastrointestinal mucosal barrier and induce immune homeostasis. Their core value proposition focuses on addressing significant unmet needs in infectious, inflammatory, and immune-mediated diseases through non-immunosuppressive therapeutic modalities.

Competitive position

Seres is a pioneer in the microbiome field, having developed the first FDA-approved oral microbiome therapeutic, VOWST, and maintains a leading reverse translational platform for LBP design.

GeographiesUnited States

Customer segmentsHospitals, Specialty clinics, Pharmaceutical companies

Business modelR&D intensive, IP licensing

SuppliersRaw material suppliers, Contract research organizations, Specialized anaerobic fermentation equipment, Clonal cell banks

CustomersPharmaceutical partners, Specialty pharmacies, Transplant centers, Academic medical centers

CountryUnited States of America

Listed2015

Employees233.0

CEORichard N. Kender

SectorHealthcare

IndustryBiotechnology

Websiteserestherapeutics.com

FilingsSEC EDGAR

Questions, answered.

What is Seres Therapeutics's market cap?: Seres Therapeutics (MCRB) has a market capitalization of $47.0M and trades on NASDAQ.
Who are Seres Therapeutics's competitors?: Seres Therapeutics's key competitors include AbbVie, Shattuck Labs, Inc. Common Stock, Spero Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Seres Therapeutics partner with?: Seres Therapeutics's notable partners include Nestlé Health Science, Memorial Sloan Kettering Cancer Center, Crohn’s and Colitis Foundation, and others.
Where is Seres Therapeutics headquartered?: Seres Therapeutics is headquartered in United States of America and employs approximately 233 people. It has been publicly traded since 2015.